You are here

Protagonist Therapeutics to Present Preclinical Results on PN-943 at the 15th Congress of European Crohn's and Colitis Organization (ECCO)

NEWARK, Calif., Feb. 7, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the Company will present preclinical data on PN-943, the Company's oral, gut-restricted, alpha-4-beta-7 inhibitor candidate therapeutic, at the 15th Congress of the European Crohn's and Colitis Organization (ECCO), which will take place Feb. 12-15, 2020, in Vienna.

Presentation details:
Title: PN-943, an Oral Alpha-4-Beta-7 Integrin Antagonist, Inhibits MAdCAM1-mediated Proliferation and Cytokine Release from CD4+ T-cells Independent of Trafficking
Location: Messe Wien Exhibition and Congress Center, Hall C - Poster exhibition   
Date: Friday, Feb. 14 
Time: 12:30-1:30 p.m. CET

About PN-943

PN-943 is an oral, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in clinical development for the treatment of inflammatory bowel disease. PN-943 is designed to offer the convenience of oral administration and the potential for improved safety and tolerability compared to antibody therapeutics administered by injection that target the alpha-4-beta-7 integrin pathway. PTG-100, a PN-943 analog, showed evidence of clinical and histological remission in patients with ulcerative colitis. PN-943 has completed Phase 1 development, demonstrating sustained target engagement with two weeks of daily administration.

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-300 is an injectable hepcidin mimetic in development for the potential treatment of iron overload anemia and related rare blood diseases including beta-thalassemia, polycythemia vera and hereditary hemochromatosis. PTG-200 is an oral, gut-restricted interleukin-23 receptor specific antagonist peptide in Phase 2 clinical development for the potential treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the clinical development of PTG-200. PN-943 is an oral, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in clinical development for the potential treatment of inflammatory bowel disease, with a Phase 2 ulcerative colitis study expected to commence in the second quarter of 2020.

Protagonist is headquartered in Newark, California. For further information, please visit http://www.protagonist-inc.com

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the potential of PN-943 as a possible treatment of inflammatory bowel disease, the potential of improved safety and tolerability for PN-943 compared to antibody therapeutics administered by injection, the potential for sustained target engagement with administration of PN-943, the results of future studies for the treatment of inflammatory bowel disease, the Company's ability to fund its clinical trials, the initiation of and enrollment of patients in the Company's clinical trials, the results of clinical trials and the outlook for our other programs. In some cases, you can identify these statements by forward-looking words such as  "will," "expect," "potential," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreement with Janssen, our ability to use and expand our programs to build a pipeline of product candidates, and our ability to obtain and maintain regulatory approval of our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading "Risk Factors" contained in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2019, filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-preclinical-results-on-pn-943-at-the-15th-congress-of-european-crohns-and-colitis-organization-ecco-300999718.html

SOURCE Protagonist Therapeutics, Inc.